BSE Live
Jan 16, 16:01Prev. Close
789.20
Open Price
792.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 16, 15:59Prev. Close
789.90
Open Price
793.00
Bid Price (Qty.)
774.90 (1)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Alembic Pharmaceuticals (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 51.42 | 32.42 | 22.38 | 22.84 | 37.03 | |
| Diluted EPS (Rs.) | 51.42 | 32.42 | 22.38 | 22.84 | 37.03 | |
| Cash EPS (Rs.) | 58.62 | 38.03 | 27.79 | 27.24 | 40.85 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 177.51 | 143.89 | 116.43 | 99.06 | 81.18 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 177.51 | 143.89 | 116.43 | 99.06 | 81.18 | |
| Dividend / Share(Rs.) | 10.00 | 5.50 | 4.00 | 4.00 | 4.00 | |
| Revenue from Operations/Share (Rs.) | 219.23 | 194.18 | 156.21 | 156.84 | 158.70 | |
| PBDIT/Share (Rs.) | 70.96 | 46.95 | 33.91 | 33.72 | 52.38 | |
| PBIT/Share (Rs.) | 63.77 | 41.35 | 28.51 | 29.33 | 48.57 | |
| PBT/Share (Rs.) | 61.90 | 40.56 | 28.39 | 29.16 | 48.45 | |
| Net Profit/Share (Rs.) | 51.43 | 32.42 | 22.39 | 22.85 | 37.03 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 32.36 | 24.18 | 21.70 | 21.50 | 33.00 | |
| PBIT Margin (%) | 29.08 | 21.29 | 18.25 | 18.69 | 30.60 | |
| PBT Margin (%) | 28.23 | 20.88 | 18.17 | 18.59 | 30.52 | |
| Net Profit Margin (%) | 23.45 | 16.69 | 14.33 | 14.56 | 23.33 | |
| Return on Networth / Equity (%) | 28.97 | 22.53 | 19.22 | 23.06 | 45.62 | |
| Return on Capital Employed (%) | 27.16 | 23.56 | 19.19 | 27.90 | 56.46 | |
| Return on Assets (%) | 16.48 | 13.43 | 11.47 | 17.17 | 31.89 | |
| Total Debt/Equity (X) | 0.50 | 0.32 | 0.28 | 0.00 | 0.00 | |
| Asset Turnover Ratio (%) | 70.29 | 80.46 | 80.06 | 117.89 | 136.66 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.48 | 1.48 | 1.91 | 2.32 | 2.31 | |
| Quick Ratio (X) | 0.74 | 0.76 | 1.15 | 1.23 | 1.37 | |
| Inventory Turnover Ratio (X) | 3.85 | 4.11 | 4.40 | 5.15 | 5.61 | |
| Dividend Payout Ratio (NP) (%) | 30.14 | 12.33 | 21.50 | 21.07 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 26.44 | 10.52 | 17.32 | 17.67 | 0.00 | |
| Earnings Retention Ratio (%) | 69.86 | 87.67 | 78.50 | 78.93 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 73.56 | 89.48 | 82.68 | 82.33 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 11,709.20 | 10,709.35 | 10,969.63 | 11,755.11 | 11,037.46 | |
| EV/Net Operating Revenue (X) | 2.83 | 2.93 | 3.73 | 3.98 | 3.69 | |
| EV/EBITDA (X) | 8.75 | 12.10 | 17.16 | 18.49 | 11.18 | |
| MarketCap/Net Operating Revenue (X) | 2.43 | 2.73 | 3.52 | 3.98 | 3.78 | |
| Retention Ratios (%) | 69.85 | 87.66 | 78.49 | 78.92 | 0.00 | |
| Price/BV (X) | 3.01 | 3.69 | 4.72 | 6.30 | 7.40 | |
| Price/Net Operating Revenue | 2.43 | 2.73 | 3.52 | 3.98 | 3.78 | |
| Earnings Yield | 0.10 | 0.06 | 0.04 | 0.04 | 0.06 |
17.11.2025
Alembic Pharma shares gain 2% on USFDA nod for Diltiazem Hydrochloride tablets
17.11.2025
10.11.2025
Alembic Pharma Standalone September 2025 Net Sales at Rs 1,796.24 crore, up 13.66% Y-o-Y
07.11.2025
Alembic Pharma Consolidated September 2025 Net Sales at Rs 1,910.15 crore, up 15.91% Y-o-Y
10.11.2025
Alembic Pharma Standalone September 2025 Net Sales at Rs 1,796.24 crore, up 13.66% Y-o-Y
07.11.2025
Alembic Pharma Consolidated September 2025 Net Sales at Rs 1,910.15 crore, up 15.91% Y-o-Y
12.08.2025
Alembic Pharma Consolidated June 2025 Net Sales at Rs 1,710.72 crore, up 9.54% Y-o-Y
05.08.2025
Alembic Pharma Standalone June 2025 Net Sales at Rs 1,494.17 crore, up 1.26% Y-o-Y
19.10.2021
Alembic Pharma Q2 PAT may dip 49.2% YoY to Rs 169.4 cr: ICICI Direct
13.07.2021
Alembic Pharmaceuticals Q1 PAT may dip 28.7% YoY to Rs 215 cr: KRChoksey
12.07.2021
Alembic Pharma Q1 PAT may dip 20.3% YoY to Rs 240.2 cr: ICICI Direct
18.01.2021
Alembic Pha Q3 PAT seen up 19.9% YoY to Rs. 280.9 cr: ICICI Direct